Trevi Therapeutics to Participate in Upcoming June Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Trevi Therapeutics (TRVI) PT Raised to $23 at Oppenheimer
June 2, 2025 4:03 PM EDTOppenheimer analyst Leland Gershall raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $23.00 (from $20.00) while maintaining a Outperform rating.
The analyst comments "Further detail to this morning's positive topline Phase 2b announcement per the company's webcast with KOL and slides... More
Trevi Therapeutics (TRVI) Falls to LOD, Down ~7pct, Raymond James: 'This is a clean win and Haduvio has now set the bar in IPF-CC'
June 2, 2025 12:18 PM EDTRaymond James analyst Ryan Deschner reiterated a Strong Buy rating and $29.00 price target on Trevi Therapeutics (NASDAQ: TRVI).
The analyst comments "Trevi reported statistically significant reductions on the 24-hr cough reduction primary endpoint in the Phase 2b CORAL study, including placebo-adjusted reductions >30% for all doses and a placebo-adjusted 43.3% reduction for the 108mg BID dose. This is a clean win and Haduvio has now... More
